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Abstract—Seipin is a widely expressed protein but with highest levels found in the brain and testes. Seipin func-
tion is not yet completely understood, therefore the aim of this study was to evaluate the expression of BSCL2
transcripts in the central nervous system (CNS) of humans and investigate the effect of their overexpression
on a neuron model and their relationship with oxidative stress protection, as well as shed light on the pathogenic
mechanisms of Celia’s Encephalopathy. We analyzed the expression of BSCL2 transcripts using real-time RT–
PCR in samples across the brain regions of subjects who underwent necropsy and from a case with Celia’s
Encephalopathy. The transcript encoding the long seipin isoform (BSCL2-203, 462 aa) is expressed primarily in
the brain and its expression is inversely correlated with age in the temporal lobe, amygdala, and hypothalamus.
Strong positive correlations were found between BSCL2 expression and some genes encoding protective
enzymes against oxidative stress including SOD1 and SOD2, as well as peroxisome proliferator-activated recep-
tor gamma (PPARG) in the amygdala. These results were experimentally corroborated by overexpressing BSCL2
transcripts in SH-SY5Y cells with lentiviral transduction and assessing their effects on neuron differentiated cells.
Confocal microscopy studies showed that both seipin and PEX16 are closely expressed in the hypothalami of
healthy human brains, and PEX16 was absent in the same region of the PELD case. We hypothesize that seipin
has specific CNS functions and may play a role in peroxisome biogenesis.  2018 The Authors. Published by Elsevier
Ltd on behalf of IBRO. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The BSCL2 gene encodes seipin, a resident endoplasmic
reticulum (ER) protein with two transmembrane domains,
a luminal loop, and two amino and carboxy-terminal tails
in the cytoplasm.
The BSCL2 gene principally encodes three seipin
isoforms under natural conditions, 462 (BSCL2-203,https://doi.org/10.1016/j.neuroscience.2018.11.004
0306-4522/ 2018 The Authors. Published by Elsevier Ltd on behalf of IBRO.
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Abbreviations: CAT, catalase; CNS, central nervous system; ER,
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biogenesis factor; PNS, peripheral nervous system; PPARG,
peroxisome proliferator-activated receptor gamma; SOD, superoxide
dismutase.
119ENST00000360796.9; CCDS44627), 398 (BSCL2-205/207/
210, ENST00000403550.5; ENST00000407022.7;
ENST00000421906.5; CCDS8031), and 287 (BSCL2-
201, ENST00000278893.11; CCDS55769) amino acids
long, respectively. BSCL2-210/207/205 was the first
transcript to be described (Magre et al., 2001), and
BSCL2-203 is the same as BSCL2-210/207/205 except
for an N-terminal extension of 64 amino acids encoded
by exon 1 and part of exon 2. The protein translated from
the short transcript is different from the other transcripts,
as exon 7 is skipped in BSCL2-201 and the reading frame
is different from exon 6 to exon 10 (Guillen-Navarro et al.,
2013).
In humans, seipin forms 12-unit homoligomers that
form a toroid (Sim et al., 2013; Sim et al., 2014). BSCL2
variants can cause different diseases, such as general-
ized congenital lipodystrophy type 2 (MIM: # 269700),
seipinopathies of first and/or second motor neurons
(MIM: # 600794, MIM: # 270685) (Ito and Suzuki, 2009),/licenses/by/4.0/).
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phy, also called Celia’s Encephalopathy (PELD, MIM:
# 615924) (Guillen-Navarro et al., 2013).
PELD is an infantile neurodegenerative disease with a
fatal prognosis before 9 years previously described by our
group (Guillen-Navarro et al., 2013). Neurological regres-
sion of Celia’s Encephalopathy begins at age 3–4, with
early signs of severe myoclonic epilepsy, spastic tetra-
paresis, and severe encephalopathy leading to death
before age 9. This disease is extraordinarily rare, and is
a consequence of the BSCL2 gene c.985C> T variant
in homozygosis or compound heterozygosis (Alaei
et al., 2016; Guillen-Navarro et al., 2013). This variant
gives rise to a branch site in exon 7 of the BSCL2 gene,
producing the intronization of that exon leading to an
aberrant seipin with a different amino acid sequence than
wild-type (BSCL2-203) from exon 6 (Guillen-Navarro
et al., 2013). The formation of large aberrant seipin
macroaggregates leading to ER stress and nuclear
accumulation of this abnormal protein are the patho-
genetic mechanisms ultimately responsible for Celia’s
Encephalopathy (Ruiz-Riquelme et al., 2015).
Seipin is a highly evolutionarily conserved protein
functioning primarily to modulate the formation of lipid
droplets and identified in yeast, Saccharomyces
cerevisiae, Caenorhabditis elegans, zebrafish, fruit fly,
and mammals (Cartwright and Goodman, 2012; Salo
et al., 2016; Wang et al., 2016). While this gene is
mainly expressed in the central nervous system (CNS),
pituitary gland, and testis in humans (Guillen-Navarro
et al., 2013; Magre et al., 2001), little is known about
the function of seipin in the CNS. Recent studies in sei-
pin KO mice have shown a particular action for this pro-
tein in the CNS that appears to be mediated by
peroxisome proliferator-activated receptor gamma
(PPARG) and that influences synaptic transmission pri-
marily through a-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid receptors, and also promotes neuronal dif-
ferentiation and modulates the behavior and motor skills
of these animals (Ebihara et al., 2015; Li et al., 2015;
Zhou et al., 2016). Here we evaluate the expression of
the various BSCL2 transcripts across human brain
regions and extraneural tissues and investigate the puta-
tive functions of seipin in the CNS.EXPERIMENTAL PROCEDURES
This study was approved by the Ethics Review panel of
Xunta de Galicia (Spain) and performed in accordance
with the ethical guidelines of the Helsinki Declaration.Tissue samples
Thirteen post-mortem donors were selected, seven men
and six women (aged 21–86 years), primarily deceased
by suicide, traffic accident, or natural causes (Table 1)
in accordance with the current Spanish legislation, and
tissue samples were obtained during autopsy conducted
within 24 h of death. Brains were removed and sliced
coronally into 12 sections. The frontal cortices in the
third slice, parietal and temporal cortices withhippocampi in the seventh slice, occipital lobes in the
eleventh, insular cortices, amygdalae, thalami, heads of
caudate and putamen nuclei, and cerebellum samples
were accurately dissected and collected separately from
both cerebral and cerebellar hemispheres, along with
the right and left sides of the hypothalamus,
mesencephalon, protuberance, and medulla oblongata,
as well as the dorsal and ventral spinal cord, anterior
pituitary, vagus and trigeminal nerves, skeletal muscles
(rectus abdominis and gastrocnemius), adipose tissue
from Bichat’s fat pad, abdominal subcutaneous tissue,
visceral areas and lower limbs, renal cortex and
medulla, and liver and gonad samples. These tissues
were immediately submerged in liquid nitrogen after
removal and subsequently stored at 80 C until RNA
preparation. These dissections yielded a total of 44
tissues for real-time RT–PCR analysis.
RNA extraction and retrotranscription
Total RNA was isolated with the ReliaPrepTM RNA Tissue
Miniprep System (Promega, Madrid, Spain). Frozen
tissue samples (20 mg of each tissue sample, except for
adipose and muscle tissues which required 100 mg)
were weighed and then homogenized in 250 ml lysis
buffer (LBA previously supplemented with 2% 1-
thioglycerol) using a Tissue Ruptor (Qiagen, Hilden,
Germany). 750 ml of Trizol reagent (Invitrogen, Madrid,
Spain) was added to the homogenized samples, which
were then vortexed for 10 s and incubated for 5 min at
room temperature to permit complete dissociation of the
nucleoprotein complex. Adipose tissue samples required
an additional centrifugation step at 12,000g for 10
minutes at 4 C to remove insoluble material, and the
fatty layer was removed and discarded while the cleared
supernatant was transferred to a new tube. 200 ml of
chloroform (Sigma, Madrid, Spain) was then added to
the supernatant, which was subsequently shaken
vigorously by hand for 15 s and incubated for 2 min at
room temperature. This was followed by a centrifugation
at 12,000g for 15 min at 4 C, after which the aqueous
phase was transferred to a new tube. 35 ml of
2-propanol (Sigma) was added for each 100 ml of
supernatant, samples were vortexed for 5 s, and the
lysate was transferred to a ReliaPrep column and
centrifuged at 14,000g for 30 s at room temperature.
Subsequent RNA purification was as follows: 200 ml of
wash solution was added followed by a centrifugation
step at 14,000g for 15 s at room temperature; 500 ml of
RNA wash solution was added and followed by
centrifugation at 14,000g for 30 s at room temperature;
300 ml of RNA wash solution was added followed by
centrifugation at 20,000g for 2 min at room temperature.
Finally, RNA was eluted with 30 ml of nuclease and
RNase-free water in a last centrifugation step performed
at 14,000g for 1 min at room temperature. The
concentration and purity of each sample was
determined by spectrophotometer (ND2000; Nanodrop),
and RNA samples were stored at 80 C until use. The
RNA was reverse transcribed using M-MLV reverse
transcriptase (Invitrogen), as previously described
(Victoria et al., 2010).
Table 1. Demographic and clinical characteristics of subjects
Subjects Gender Age Height (cm) Weight (kg)
1 Woman 67 165 65
2 Man 73 160 80
3 Man 40 167 75
4 Woman 83 160 90
5 Man 29 184 90
6 Man 61 165 90
7 Man 21 184 80
8 Woman 86 169 69
9 Man 43 178 120
10 Man 43 174 80
11 Woman 21 153 65
12 Woman 66 154 73
13 Woman 77 150 60
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Specific primers and probes designed by the Universal
ProbeLibrary (Roche Diagnostics, Sant Cugat del
Valles, Spain) were used in a Light Cycler 2.0 (Roche
Diagnostics) to determine the specific expression of the
following genes: CAT, NESTIN, PEX1, PEX11G,
PEX16, PPARG, RBFOX3/NeuN, SOD1, SOD2
(Table 2), and three distinct BSCL2 transcripts (Fig. 1).
Real-time RT–PCR conditions are available upon
request. Results were normalized to the 18S and RNA
polymerase II genes using the 2DD CT method (Livak
and Schmittgen, 2001).Cell culture
The SH-SY5Y neuroblastoma cell line was kindly
provided by Dr. Jesús Rodrı́guez-Requena (Santiago de
Compostela, Spain). Undifferentiated cells were
maintained in a 1:1 mixture of Ham’s F12 (cat. N4888,
Sigma–Aldrich) and Minimum Essential Eagle’s Medium
(cat. M2279, Sigma–Aldrich) supplemented with 15%
heat-inactivated fetal bovine serum (cat. 10270-106,
Gibco), 1% GlutaMax-ITM (cat. 35050-061, Gibco),
100 units/ml penicillin, 100 mg/ml streptomycin (cat.Table 2. Primer sequences and probes
Genes Forward Primer Reverse Prim
18S GCAATTATTCCCCATGAACG GGGACTTAA
BSCL2 ex1 AGGAGGAAGCTGGGGAAA CAGCAGCTG
BSCL2 ex7 TGCGCCTTCATAGGTGTTG ACCCACTGC











Primer sequences and probes from Universal ProbeLibrary used in qPCR analysis.15140-122, Gibco), and 1% MEM non-essential amino
acids solution (NEAA, cat. 11140050, Gibco). Cells
were grown in the presence of 5% CO2 in a humidified
incubator at 37 C. The cell medium was replaced every
3 days, and the cells were sub-cultured once 90%
confluence was reached. The cells were used at early
passages (below P17) in all experiments.
Plasmids
A plasmid containing wild-type human seipin fused to a
myc tag (6x myc-wt seipin pCS2+MT) was generously
provided by D. Ito (Keio University, Japan), and the myc
fused seipin expression plasmid was described
previously (Guillen-Navarro et al., 2013). The wild-type
lentiviral plasmid was generated as follows: wt seipin
cDNA was amplified by PCR using specific primers
(forward: 50-TAAGCAGGTACCTCTTTTTGCAGGATCC
CATCGA-30; reverse: 50- TAAGCATCTAGAGCCTT
GAATTCGCCCTTGAC-30), then digested with the fast-
digest restriction enzymes KpnI and XbaI (cat. FD0524
and FD0684, ThermoFisher Scientific), and purified and
inserted into pLenti-CMV-GFP-2A-Puro-Blank (cat.
LV073, Applied Biological Materials Inc.) vector. This






TCAACGCAAGC 48 TTCCCAGT 68
GTGGTTCCT 54 CTGGTCTC 78
ATGTAGCTGAA 73 TCCTCAGC 74
GTTAACCTGAGC 42 CATCCAGC 96
TCCTTCAGATG 76 TGGCTGTG 76
TCGCTCTCTTC 69 CTTCCTCC 77
TGAAGTTCTTTCAT 54 CTGGTCTC 88
CCACCAACCAG 74 CTGCTGCC 80
TCCGGTCTTAG 73 TCCTCAGC 143
TTGTAGAGCTGAGTC 39 CTCCACCT 95
CTTCGTCCT 1 CCTGGAGC 68
TTGTCCACCAC 69 CTTCCTCC 86
AGGATTAAAGTGAGGA 40 CAGCAGGC 74
TAGGGCAGGT 1 CCTGGAGC 118
Fig. 1. Three main transcripts of the BSCL2 gene. The BSCL2-203 transcript (ENST00000360796.9; CCDS44627) contains 11 exons coding for a 462-amino-acid-long protein. The BSCL2-205/207/
210 transcript (ENST00000403550.5; ENST00000407022.7; ENST00000421906.5; CCDS8031) is identical to BSCL2-203 except that it lacks the first 192 nucleotides (exon 1 and part of exon 2 of
BSCL2-203), resulting in a 398-amino-acid-long protein. The BSCL2-201 transcript (ENST00000278893.11; CCDS55769) features exon 7 skipping and generates a protein of 287 amino acids. The
probe #73 (TCCTCAGC) used with forward: 50-TGCGCCTTCATAGGTGTTG-30 and reverse primer: 50-ACCCACTGCATGTAGCTGAA-30 hybridizes with exon 7 of BSCL2 gen (amplicon 74
nucleotides), while the reverse primer: 50-AGCGATCATTGAGATCCACA-30 used with the probe #42 (CATCCAGC) and the forward primer: 50-TTTTCGGATGTTAACCTGAGC-30 hybridizes with the
union of exon 6 and exon 8 (amplicon 96 nucleotides). The probe #54 (GAGACCAG) used with the forward: 50-AGGAGGAAGCTGGGGAAA-30 and the reverse primer: 50-CAGCAGCTGGTGGTTCCT-
30 (amplicon 78 nucleotides) hybridizes with exon 1 of BSCL2 gen. Expression of BSCL2-203 transcript corresponds to the values obtained from real-time RT–PCR using the probe #54. Expression of
BSCL2-205/207/210 transcript was calculated by subtracting the values obtained from real-time RT–PCR using probe #73 minus the values obtained from real-time RT–PCR using probe #54.














































Fig. 2. Lentiviral BSCL2 plasmid. Plasmid map of lentiviral expression vector used in this study. This
pLenti vector includes a CMV promoter for robust and consistent ORF expression, a GFP reporter
driven by a separate promoter to the gene of interest to monitor transfection and infection, and a
selectable marker expression that confers puromycin resistance.
S. Sánchez-Iglesias et al. / Neuroscience 396 (2019) 119–137 123incompetent third-generation vector, and is depicted in
Fig. 2. Full sequences were confirmed by sequencing.
Lentiviral transduction
Cells were seeded into 6-well plates (cat. 3516, Corning,
Costar) at a density of 5000 cells per cm2. The medium
was removed twenty-four hours after seeding and the
cells were washed with phosphate-buffered saline
(PBS). Viral particles (wild-type seipin), and the empty
vector as a control, all with functional titers >109
transducing units/ml produced by Cyagen Biosciences
(Guangzhou, China) were added at a multiplicity of
infection (MOI) of 200 viral particles/cell to a serum-free
medium in the presence of Lentiblast A/B (1:100/1:1000,
Oz Biosciences, Marseille, France). Serum was added 4
hours after initial infection (final infection volume 1 ml),
the medium was removed twenty-four hours after
infection, and the cells were washed with phosphate-
buffered saline (PBS). Cells were then cultured with
typical SH-SY5Y medium and puromycin
dihydrochloride (2 lg/ml final concentration, cat. P8833,
Sigma–Aldrich) was subsequently added to the cell
culture medium every 2–3 days until resistant stable
cells were formed. Cells were then routinely grown as
described above.Differentiation
Stably transfected cells were seeded into six-well plates
at density of 10,000 cells per cm2 and allowed to adhere
for 2 days. Pre-differentiation was then started in DMEM
high glucose (D5796, Sigma–Aldrich) supplemented with
3% heat-inactivated fetal bovine serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin with 10 mM
retinoic acid (cat. R2625, Sigma–Aldrich), freshly
prepared in DMSO and kept in the dark.
Undifferentiated cells were cultured in identical medium
without retinoic acid. The second phase of differentiation
was initiated after 3 days in these conditions (day 4)
with Neurobasal medium (cat. 21103-049, Gibco),
50 ng/ml BDNF (cat. 450-02, Peprotech), 1 mM
dibutyryl-cAMP (cat. sc-201567A, Santa Cruz), 20 mM
KCl (cat. 131494, Panreac), 10 mM retinoic acid, 1%
B27 (cat. 17504-044, Gibco), 1% Glutamax 100, 1%
N-2 supplement (cat. 17502-048, Gibco), 100 units/ml
penicillin, and 100 mg/ml streptomycin. Undifferentiatedcells were maintained in high
glucose DMEM, supplemented
with 1% heat-inactivated fetal
bovine serum, 100 units/ml penicillin,
and 100 mg/ml streptomycin. The
culture medium was changed
every 2 days and supplemented
with fresh additives. Differences in
cell morphology between prolife-
rative and differentiated cells were
evaluated under phase contrast
light microscopy with an Olympus
IX51 microscope (Olympus
Corporation, Tokyo, Japan) and
photographed with an Olympus
DP72 digital camera using thecellSens software (Olympus Corporation). Cells were
harvested on day 8.
Immunostaining
The hypothalamus of the homozygous index case
c.985C> T and of two control cases (male and female,
59 and 75 years at death, respectively) were fixed
previously with 10% neutral buffered formalin (Bio-
Optica, cat. 05-K01022) for 24 h at room temperature
and embedded in paraffin. After deparaffinization and
rehydration, slides were pre-treated with PT-link (Dako,
California, USA) for 20 min at 95 C in Tris/EDTA buffer,
pH 9. Slides were then washed four times with PBS and
incubated with 1:250 anti PEX16 antibody (Santa Cruz
Biotechnology) and 1:125 anti-seipin antibody
HPA042394 (Sigma–Aldrich, The Human Protein Atlas)
overnight at 4 C. The next day, the slides were washed
four times with PBS and incubated with Alexa Fluor 555
(Thermo-Fisher Scientific, cat. A31572) conjugated anti-
mouse secondary antibody, and Alexa Fluor 488
(Thermo-Fisher Scientific, cat. A21202) conjugated anti-
rabbit secondary antibody for 1 h in darkness, washed
with double-distilled water. Slides were then treated to
quench autofluorescence background with 0.1% Sudan
Black B (Sigma, cat. 199664) in 70% ethanol for less
than 5 min at room temperature and washed three
times, for 5 min each with double-distilled water. Finally,
they were mounted in aqueous medium containing
1:1000 DAPI (Sigma–Aldrich, cat. D9542).Confocal fluorescence microscopy
Immunofluorescence staining was assessed with a Leica
TCS SP2 confocal microscope using a HCX PL APO
63/1.3 glycerol-immersion objective and Leica
Confocal Software (Leica Microsystems Heidelberg
GmbH, Mannheim, Germany). Images were obtained by
a sequential scan method and three different laser lines
to avoid simultaneous excitation and possible overlap.
Confocal acquisition of the fluorescence labels was
performed as follows: DAPI, color-coded in blue
(Blue-Diode, excited at 405 nm and recorded on 425–
470 nm), Alexa Fluor 488 nm, color-coded in green
(Argon laser, excited at 488 nm and recorded at 500–
555 nm), and Alexa Fluor 555 nm, color-coded in red
Fig. 3. BSCL2 transcripts’ expression. (A) Summary of the relative expression of the three BSCL2 transcripts across the primary brain divisions, the peripheral nervous system (PNS), and the
extraneural tissues (ET). Details are available in Table 3. (B) Percent expression of BSCL2 transcripts in CNS, PNS and ET. BSCL2-203 (blue), BSCL2-205/207/210 (red), and BSCL2-201 (green)
expression are referred to as BSCL2 total expression. (C) Percentage expression of BSCL2 transcripts in primary brain divisions: telencephalon (T), diencephalon (D), mesencephalon (M),
metencephalon (Me), myelencephalon (My), spinal cord (SC); peripheral nervous system (PNS) and extraneural tissues (ET). All samples were analyzed in duplicate, n= 13. All results were normalized
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675 nm). Two random visual fields were analyzed for
each group.Statistical analysis
Real-time PCR analyses were done by duplicates, and
statistical significance was determined using a non-
parametric Kruskal–Wallis test followed by a Mann–
Whitney U post-hoc with Bonferroni’s correction.
Correlations were tested using the Spearman R
correlation coefficient and partial correlations were
utilized to correlate two variables while adjusting for
other one. Data are presented as mean ± SD withTable 3. Relative expression of BSCL2 transcripts
# Tissues BSCL2-203
1 Frontal Lobe R 1.222 ± 0.723*,#
2 Frontal lobe L 0.977 ± 0.799*,#
3 Parietal lobe R 1.423 ± 0.827*,#
4 Parietal lobe L 1.269 ± 0.895*,#
5 Temporal lobe R 1.177 ± 0.709*,#
6 Temporal lobe L 1.012 ± 0.574*,#
7 Occipital lobe R 1.051 ± 0.820*,#
8 Occipital lobe L 0.859 ± 0.775*,#
9 Insula R 1.306 ± 0.905*,#
10 Insula L 1.178 ± 0.680*,#
11 Amygdala R 1.046 ± 0.643*,#
12 Amygdala L 1.116 ± 0.744*,#
13 Thalamus R 0.955 ± 0.521*,#
14 Thalamus L 0.667 ± 0.448*,#
15 Caudate R 1.459 ± 0.729*,#
16 Caudate L 1.852 ± 0.933*,#
17 Putamen R 1.441 ± 0.660*,#
18 Putamen L 1.292 ± 0.520*,#
19 Hypothalamus R 0.981 ± 0.645*,#
20 Hypothalamus L 0.746 ± 0.461*,#
21 Pituitary 2.021 ± 0.716*,#
22 Cerebellum R 1.172 ± 0.793*,#
23 Cerebellum L 1.521 ± 0.879*,#
24 Mesencephalon R 0.611 ± 0.524*,#
25 Mesencephalon L 0.804 ± 0.777*,#
26 Protuberance R 1.680 ± 1.022*,#
27 Protuberance L 1.559 ± 0.932*,#
28 Medulla oblongata R 0.711 ± 0.554*,#
29 Medulla oblongata L 0.816 ± 0.620*,#
30 Spinal cord D 0.397 ± 0.275*,#
31 Spinal cord V 0.472 ± 0.405*,#
32 Bichat fat pad 0.033 ± 0.008*,#
33 SC abdominal fat 0.025 ± 0.026*,#
34 SC L.L. fat 0.029 ± 0.012*,#
35 Visceral fat 0.025 ± 0.013#
36 Rectus abdominis muscle 0.050 ± 0.015*,#
37 Gastrocnemius muscle 0.034 ± 0.016#
38 Myocardium 0.015 ± 0.006*,#
39 Liver 0.019 ± 0.009*,#
40 Vagus nerve 0.085 ± 0.035#
41 Trigeminal nerve 0.239 ± 0.144*,#
42 Renal cortex 0.075 ± 0.023#
43 Renal medulla 0.092 ± 0.051*,#
44 Gonads 0.427 ± 0.456#
Relative expression of the three BSCL2 transcripts in encephalic and non-encephalic post-
transcripts; #p< 0.05, BSCL2-203 transcript referred to BSCL2-201 transcript; §p< 0.05
were analyzed in duplicate, n= 13. Results were normalized for the 18S gene. R: right,statistical significance set at p< 0.05. All statistical
analyses were performed using SPSS for Mac (release
22.0; SPSS, Chicago, IL, USA).RESULTS
Patterns of BSCL2 expression in human tissues
We evaluated the relative expression of seipin transcripts
in the CNS, the peripheral nervous system (PNS), and
extraneural tissues (ET) in 13 subjects (Fig. 3A, detailed
with significance in Table 3). The total expression of
BSCL2 was 6.9 times higher in the CNS than in any of
the other tissues (p< 0.001): 86.3% in CNS, 1.3% inBSCL2-205/207/210 BSCL2-201
0.0107 ± 0.0375* 0.0058 ± 0.00379#
0.0812 ± 0.160* 0.0082 ± 0.0077#
0.0206 ± 0.059*,§ 0.0081 ± 0.005#,§
0.110 ± 0.159*,§ 0.01 ± 0.0082#,§
0.0197 ± 0.041*,§ 0.0051 ± 0.0029#,§
0.19 ± 0.199*,§ 0.0054 ± 0.0036#,§
0.0732 ± 0.240*,§ 0.0058 ± 0.0053#,§
0.0642 ± 0.127*,§ 0.0072 ± 0.0053#,§
0.301 ± 0.305*,§ 0.0067 ± 0.004#,§
0.0756 ± 0.084*,§ 0.0083 ± 0.0073#,§
0.0511 ± 0.066*,§ 0.0048 ± 0.0032#,§
0.037 ± 0.079*,§ 0.0052 ± 0.0033#,§
0.0669 ± 0.0830*,§ 0.007 ± 0.0059#,§
0.0889 ± 0.071*,§ 0.014 ± 0.022#,§
0.044 ± 0.094* 0.0194 ± 0.0178#
0.0268 ± 0.0760* 0.0126 ± 0.0076#
0.1228 ± 0.1841*,§ 0.0088 ± 0.0047#,§
0.0686 ± 0.198*,§ 0.0079 ± 0.0039#,§
0.1 ± 0.1449*,§ 0.0076 ± 0.0056#,§
0.0937 ± 0.083*,§ 0.0065 ± 0.0054#,§
0.1451 ± 0.214*,§ 0.0130 ± 0.0055#,§
0.1584 ± 0.427*,§ 0.0147 ± 0.0192#,§
0.0566 ± 0.1220* 0.0104 ± 0.0074#
0.1804 ± 0.126*,§ 0.0072 ± 0.0066#,§
0.07126 ± 0.0928*,§ 0.0068 ± 0.0066#,§
0.0773 ± 0.197*,§ 0.0106 ± 0.0068#,§
0.189 ± 0.290*,§ 0.0122 ± 0.0088#,§
0.1176 ± 0.151*,§ 0.00358 ± 0.0035#,§
0.128 ± 0.1324*,§ 0.004 ± 0.0041#,§
0.0561 ± 0.050*,§ 0.0023 ± 0.0023#,§
0.1467 ± 0.086*,§ 0.0034 ± 0.0024#,§
0.1165 ± 0.052*,§ 0.00048 ± 0.00023#,§
0.0836 ± 0.041*,§ 0.003 ± 0.0029#,§
0.144 ± 0.054*,§ 0.0014 ± 0.0007#,§
0.09 ± 0.074§ 0.0015 ± 0.00097#,§
0.123 ± 0.0709*,§ 0.00159 ± 0.00079#,§
0.0479 ± 0.045§ 0.005 ± 0.0092#,§
0.0357 ± 0.0165*,§ 0.0004 ± 0.0002#,§
0.038 ± 0.0227*,§ 0.0005 ± 0.00032#,§
0.0924 ± 0.041§ 0.0005 ± 0.0002#,§
0.1239 ± 0.097*,§ 0.0019 ± 0.0016#,§
0.378 ± 0.786§ 0.0023 ± 0.0018#,§
0.4049 ± 0.507*,§ 0.0053 ± 0.0049#,§
0.651 ± 0.647§ 0.0057 ± 0.0044#,§
mortem tissues. *p< 0.05, BSCL2-203 transcript referred to BSCL2-205/207/210
, BSCL2-205/207/210 transcripts referred to BSCL2-201 transcript. All samples
L: left, V: ventral, D: dorsal, L.L.: lower limbs, SC: subcutaneous.
Table 4. BSCL2 transcripts expression in men and women
Tissues Side BSCL2-203 BSCL2-205/207/210 BSCL2-201
Male (n= 7) Female (n= 6) D% Male (n= 7) Female (n= 6) D% Male (n= 7) Female (n= 6) D%
Frontal lobe R 1.27 ± 0.83 1.17 ± 0.62 0.02 ± 0.05 0 0.006 ± 0.005 0.005 ± 0.002
L 1.14 ± 0.87 0.79 ± 0.69 0.045 ± 0.14* 0.124 ± 0.177 63 0.0089 ± 0.005 0.0074 ± 0.01
Parietal lobe R 1.27 ± 0.93 1.59 ± 0.68 0.028 ± 0.078 0.012 ± 0.029 0.0066 ± 0.0053 0.0099 ± 0.0044
L 1.12 ± 0.93 1.44 ± 0.85 0.074 ± 0.108 0.15 ± 0.20 0.0086 ± 0.0084 0.0126 ± 0.0078
Temporal lobe R 1.41 ± 0.74* 0.899 ± 0.58 +57 0.023 ± 0.045 0.016 ± 0.038 0.0058 ± 0.0028 0.0044 ± 0.0030
L 1.185 ± 0.6* 0.81 ± 0.49 +46 0.30 ± 0.20* 0.059 ± 0.096 +408 0.0062 ± 0.0037 0.0045 ± 0.0035
Occipital lobe R 0.92 ± 0.7 1.2 ± 0.95 0.009 ± 0.024 0.15 ± 0.35 0.0041 ± 0.0024 0.0080 ± 0.0070
L 0.69 ± 0.58 1.06 ± 0.94 0.036 ± 0.037 0.097 ± 0.18 0.0072 ± 0.0061 0.0072 ± 0.0046
Insula R 1.51 ± 0.91 1.07 ± 0.88 0.40 ± 0.35 0.19 ± 0.20 0.0071 ± 0.0031 0.0059 ± 0.0049
L 1.18 ± 0.67 1.17 ± 0.73 0.109 ± 0.087* 0.037 ± 0.064 +194 0.0087 ± 0.0077 0.0080 ± 0.0072
Amygdala R 1.24 ± 0.62 0.77 ± 0.60 0.067 ± 0.078 0.029 ± 0.038 0.0056 ± 0.0034 0.0039 ± 0.0028
L 1.39 ± 0.73 0.73 ± 0.59 0.034 ± 0.058 0.42 ± 0.11 0.0057 ± 0.0032 0.0046 ± 0.0036
Thalamus R 1.03 ± 0.49 0.87 ± 0.57 0.065 ± 0.086 0.069 ± 0.083 0.0084 ± 0.0072 0.0056 ± 0.0040
L 0.63 ± 0.36 0.71 ± 0.55 0.12 ± 0.056 0.05 ± 0.07 0.0189 ± 0.0289 0.0083 ± 0.0079
Caudate R 1.59 ± 0.56 1.31 ± 0.89 0.042 ± 0.094 0.047 ± 0.099 0.0158 ± 0.0143 0.0238 ± 0.0212
L 2.24 ± 0.95 1.40 ± 0.70 0.018 ± 0.048 0.037 ± 0.1 0.0139 ± 0.0058 0.0112 ± 0.0095
Putamen R 1.65 ± 0.66 1.2 ± 0.59 0.149 ± 0.208 0.093 ± 0.156 0.0098 ± 0.0044 0.0078 ± 0.0052
L 1.29 ± 0.51 1.30 ± 0.56 0.02 ± 0.03 0.125 ± 0.287 0.0075 ± 0.0037 0.0084 ± 0.0044
Hypothalamus R 0.97 ± 0.56 1.0 ± 0.76 0.108 ± 0.13 0.091 ± 0.166 0.0072 ± 0.0048 0.0083 ± 0.0067
L 0.87 ± 0.46 0.61 ± 0.43 0.13 ± 0.066* 0.051 ± 0.084 +155 0.0080 ± 0.0064 0.0049 ± 0.0035
Pituitary 1.97 ± 0.79 2.08 ± 0.66 0.193 ± 0.270 0.089 ± 0.11 0.0099 ± 0.0037* 0.0166 ± 0.0052 40
Cerebellum R 0.94 ± 0.80 1.44 ± 0.72 0.077 ± 0.13 0.25 ± 0.61 0.0076 ± 0.0067* 0.0230 ± 0.0255 67
L 1.53 ± 0.84 1.51 ± 0.97 0.07 ± 0.155 0.042 ± 0.071 0.0116 ± 0.0090 0.0091 ± 0.0052
Mesencephalon R 0.53 ± 0.52 0.71 ± 0.53 0.198 ± 0.142 0.16 ± 0.11 0.0062 ± 0.0073 0.0084 ± 0.0059
L 0.90 ± 0.90 0.69 ± 0.63 0.066 ± 0.09 0.078 ± 0.099 0.0074 ± 0.0075 0.0062 ± 0.0058
Protuberance R 1.99 ± 0.95 1.32 ± 1.03 0.121 ± 0.256 0.027 ± 0.077 0.0123 ± 0.0071 0.0087 ± 0.0063
L 1.7 ± 0.75 1.39 ± 1.12 0.17 ± 0.17 0.21 ± 0.39 0.0140 ± 0.0090 0.0103 ± 0.0086
Medulla oblongata R 0.83 ± 0.63 0.54 ± 0.41 0.153 ± 0.156 0.076 ± 0.139 0.0043 ± 0.0044 0.0027 ± 0.0019
L 0.96 ± 0.64 0.64 ± 0.57 0.168 ± 0.16 0.084 ± 0.074 0.0051 ± 0.0049 0.0028 ± 0.0025
Spinal cord D 0.42 ± 0.32 0.37 ± 0.22 0.070 ± 0.052 0.040 ± 0.044 0.0017 ± 0.0009 0.0031 ± 0.0032
V 0.66 ± 0.46* 0.25 ± 0.17 +164 0.182 ± 0.088* 0.106 ± 0.066 +71 0.0044 ± 0.0027 0.0023 ± 0.0016
Bichat fat pad – 0.034 ± 0.010 0.033 ± 0.008 0.135 ± 0.054 0.095 ± 0.053 0.0004 ± 0.0002 0.0006 ± 0.0003
SC abdominal fat – 0.034 ± 0.034 0.016 ± 0.003 0.10 ± 0.047* 0.059 ± 0.012 +69 0.0032 ± 0.0033 0.0028 ± 0.0026
SC lower limbs fat – 0.029 ± 0.009 0.030 ± 0.015 0.145 ± 0.042 0.144 ± 0.068 0.0016 ± 0.0007 0.0012 ± 0.0007
Visceral fat – 0.030 ± 0.013* 0.020 ± 0.013 33 0.091 ± 0.028 0.090 ± 0.11 0.0012 ± 0.0007 0.0019 ± 0.0011
Rectus abdominis muscle – 0.047 ± 0.019 0.054 ± 0.008 0.092 ± 0.039* 0.16 ± 0.08 42 0.0016 ± 0.0009 0.0016 ± 0.0007
Gastrocnemius muscle – 0.034 ± 0.016 0.035 ± 0.019 0.056 ± 0.056 0.039 ± 0.030 0.0031 ± 0.0051 0.0073 ± 0.0123
Myocardium – 0.016 ± 0.009 0.014 ± 0.003 0.037 ± 0.01 0.035 ± 0.022 0.0005 ± 0.0002 0.0004 ± 0.0002
Liver – 0.021 ± 0.01 0.018 ± 0.009 0.041 ± 0.022 0.036 ± 0.024 0.0005 ± 0.0004 0.0005 ± 0.0003
Vagus nerve – 0.10 ± 0.03* 0.07 ± 0.03 +43 0.117 ± 0.032* 0.064 ± 0.031 +83 0.0005 ± 0.0002 0.0006 ± 0.0003
Trigeminal nerve – 0.25 ± 0.18 0.23 ± 0.09 0.16 ± 0.10* 0.077 ± 0.070 +108 0.0021 ± 0.0019 0.0017 ± 0.0013
Renal cortex – 0.085 ± 0.026 0.064 ± 0.014 0.57 ± 1.05 0.16 ± 0.052 0.0029 ± 0.0023 0.0018 ± 0.0009
Renal medulla – 0.089 ± 0.053 0.096 ± 0.051 0.42 ± 0.56 0.39 ± 0.46 0.0037 ± 0.0025 0.0072 ± 0.0064
Gonads – 0.51 ± 0.14* 0.33 ± 0.66 +54 1.17 ± 0.42* 0.044 ± 0.051 +2559 0.0089 ± 0.0030* 0.0020 ± 0.003 +345














































Table 5. BSCL2 transcripts expression in young and old subjects (median age 61 years)
Tissues Side BSCL2-203 BSCL2-205/207/210 BSCL2-201
<61 y. (n= 6) 61 y. (n= 7) D% <61 y. (n= 6) 61 y. (n= 7) D% <61 y. (n= 6) 61 y. (n= 7) D%
Frontal lobe R 1.68 ± 0.69* 0.83 ± 0.49 51 0.023 ± 0.053 0.0003 ± 0.001 0.0079 ± 0.004* 0.004 ± 0.0025 49
L 0.99 ± 0.72 0.96 ± 0.89 0.07 ± 0.18 0.088 ± 0.15 0.009 ± 0.0049 0.0075 ± 0.0096
Parietal lobe R 1.71 ± 0.76 1.18 ± 0.83 0.03 ± 0.08 0.012 ± 0.03 0.009 ± 0.004 0.007 ± 0.0055
L 1.39 ± 1.08 1.17 ± 0.73 0.15 ± 0.19 0.076 ± 0.124 0.011 ± 0.009 0.01 ± 0.007
Temporal lobe R 1.5 ± 0.57* 0.9 ± 0.72 40 0.014 ± 0.032 0.024 ± 0.048 0.0065 ± 0.002* 0.0038 ± 0.0028 42
L 1.48 ± 0.28* 0.61 ± 0.43 58 0.33 ± 0.20* 0.069 ± 0.09 79 0.0076 ± 0.0025* 0.0035 ± 0.003 54
Occipital lobe R 1.14 ± 0.66 0.97 ± 0.95 0.02 ± 0.046 0.12 ± 0.32 0.005 ± 0.0028 0.006 ± 0.0068
L 0.93 ± 0.77 0.8 ± 0.80 0.019 ± 0.025 0.102 ± 0.17 0.0083 ± 0.0064 0.0061 ± 0.004
Insula R 1.72 ± 0.79* 0.95 ± 0.87 45 0.42 ± 0.3 0.19 ± 0.27 0.0084 ± 0.0028 0.0052 ± 0.004
L 1.25 ± 0.55 1.11 ± 0.79 0.099 ± 0.1 0.054 ± 0.06 0.0081 ± 0.0068 0.0086 ± 0.0079
Amygdala R 1.44 ± 0.39* 0.66 ± 0.62 54 0.079 ± 0.078 0.023 ± 0.035 0.0064 ± 0.0028* 0.0033 ± 0.0028 48
L 1.59 ± 0.53* 0.65 ± 0.63 59 0.072 ± 0.1* 0.0019 ± 0.007 97 0.0075 ± 0.0029* 0.0029 ± 0.0019 61
Thalamus R 1.21 ± 0.26* 0.73 ± 0.59 40 0.087 ± 0.089 0.049 ± 0.076 0.0099 ± 0.0067 0.0046 ± 0.0039
L 0.7 ± 0.24 0.64 ± 0.58 0.135 ± 0.06* 0.049 ± 0.055 64 0.0213 ± 0.030 0.0077 ± 0.0076
Caudate R 1.85 ± 0.27* 1.12 ± 0.83 39 0.049 ± 0.10 0.04 ± 0.092 0.0121 ± 0.0084 0.0258 ± 0.0214
L 2.36 ± 0.73* 1.41 ± 0.87 40 0.022 ± 0.05 0.031 ± 0.093 0.0160 ± 0.0044* 0.0097 ± 0.0087 39
Putamen R 1.81 ± 0.35* 1.13 ± 0.71 38 0.10 ± 0.16 0.14 ± 0.21 0.0108 ± 0.0031 0.0072 ± 0.005
L 1.48 ± 0.26 1.13 ± 0.63 0.022 ± 0.035 0.108 ± 0.27 0.0086 ± 0.003 0.0072 ± 0.004
Hypothalamus R 1.2 ± 0.35 0.79 ± 0.78 0.099 ± 0.14 0.101 ± 0.15 0.0089 ± 0.0035 0.0066 ± 0.0069
L 1.13 ± 0.27* 0.41 ± 0.30 64 0.097 ± 0.075 0.091 ± 0.09 0.0101 ± 0.0055* 0.0035 ± 0.0030 65
Pituitary – 2.05 ± 0.46 2.0 ± 0.89 0.22 ± 0.28 0.08 ± 0.11 0.0121 ± 0.0025 0.0137 ± 0.007
Cerebellum R 1.11 ± 0.88 1.22 ± 0.73 0.045 ± 0.056 0.26 ± 0.57 0.008 ± 0.006 0.0199 ± 0.024
L 1.63 ± 0.72 1.42 ± 1.00 0.08 ± 0.166 0.036 ± 0.067 0.013 ± 0.0085 0.0079 ± 0.0055
Mesencephalon R 0.64 ± 0.51 0.58 ± 0.54 0.23 ± 0.13 0.14 ± 0.11 0.008 ± 0.007 0.006 ± 0.005
L 1.14 ± 0.93 0.52 ± 0.47 0.117 ± 0.11* 0.032 ± 0.052 73 0.0097 ± 0.008 0.0043 ± 0.0038
Protuberance R 2.33 ± 0.50* 1.12 ± 1.03 52 0.128 ± 0.28 0.033 ± 0.073 0.014 ± 0.0055 0.0077 ± 0.0066
L 2.1 ± 0.39* 1.09 ± 1.01 48 0.194 ± 0.18 0.185 ± 0.37 0.0173 ± 0.007* 0.0078 ± 0.0077 55
Medulla oblongata R 1.12 ± 0.43* 0.35 ± 0.37 69 0.156 ± 0.17 0.085 ± 0.13 0.0056 ± 0.004* 0.0018 ± 0.0017 68
L 1.22 ± 0.57* 0.47 ± 0.43 61 0.17 ± 0.17 0.095 ± 0.089 0.0066 ± 0.0047* 0.0018 ± 0.0014 72
Spinal cord D 0.42 ± 0.17 0.38 ± 0.35 0.053 ± 0.052 0.059 ± 0.05 0.0018 ± 0.0006 0.003 ± 0.003
V 0.72 ± 0.44* 0.26 ± 0.23 63 0.196 ± 0.09* 0.104 ± 0.058 47 0.005 ± 0.0022* 0.0021 ± 0.0018 58
Bichat fat pad – 0.033 ± 0.009 0.033 ± 0.009 0.136 ± 0.056 0.1 ± 0.044 0.0004 ± 0.0002 0.0005 ± 0.0003
SC abdominal fat – 0.036 ± 0.036 0.017 ± 0.007 0.095 ± 0.041* 0.073 ± 0.041 23 0.0023 ± 0.002 0.0036 ± 0.0033
SC lower limbs fat – 0.029 ± 0.007 0.03 ± 0.015 0.167 ± 0.053 0.124 ± 0.049 0.0017 ± 0.0006* 0.0011 ± 0.0006 35
Visceral fat – 0.03 ± 0.01* 0.020 ± 0.01 33 0.130 ± 0.086* 0.056 ± 0.039 57 0.0013 ± 0.0009 0.0017 ± 0.001







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































128 S. Sánchez-Iglesias et al. / Neuroscience 396 (2019) 119–137PNS, and 12.4% in ET (Fig. 3B), and the pituitary and the
gonads had the highest total BSCL2 expression of the
non-neural tissues (5.25% and 2.61%, respectively).
The predominant transcript is BSCL2-203 (6.8), which
encodes the long isoform and represents 86.6% of total
BSCL2 transcript expression (Fig. 3B). BSCL2-203 was
expressed most in the CNS (78.9% of total BSCL2
expression, and 91.2% of BSCL2-203 expression)
(Fig. 3B, C) and was higher in the caudate nuclei and in
the protuberance (9.2% and 9% of BSCL2-203
expression, respectively). BSCL2-203 expression in the
PNS and ET was 0.9% and 7.9%, respectively
(Fig. 3C). BSCL2-205/207/210 expression represented
only 12.7% of total BSCL2 expression (Fig. 3B) and was
expressed the most in ET and the PNS (42.6% and 4.1%
of BSCL2-205/207/210 expression, respectively)
(Fig. 3C). BSCL2-205/207/210 expression was
increased 3.9 and 2 respectively in adipose and
muscle tissues, compared to BSCL2-203, and BSCL2-
201 expression was low in all tissues (0.7% of total
BSCL2 expression, Fig. 3B). Within the CNS, the short
transcript was primarily expressed in the caudate
nucleus, the cerebellum, and the protuberance.
Expression levels of BSCL2 transcripts across the
primary brain divisions are summarized in Fig. 3C.
A comparison of BSCL2 expression between men and
women (Table 4) shows that the three transcripts are
expressed more highly in the testicles than in the
ovaries (BSCL2-203: +54%, p= 0.003; BSCL2-
205/207/210: +2559%, p= 0.0001; BSCL2-201:
+345%, p= 0.0001), and BSCL2-203 and BSCL2-
205/207/210 are more expressed in the ventral spinal
cord in men than in women (+164%, p= 0.008; and
+71%, p= 0.02, respectively). BSCL2-203 expression
is significantly higher in the temporal lobe in men than
in women (Right: +57%, p= 0.046; Left: +46%,
p= 0.04), the visceral fat (–33%, p= 0.023), and the
vagus nerve (+43%, p= 0.017) (Table 4). BSCL2-
205/207/210 expression in the left temporal lobe
(+408%, p= 0.01), left insula (+194%, p= 0.01), left
hypothalamus (+155%, p= 0.01), subcutaneous
abdominal fat (+69%, p= 0.003), and vagus and
trigeminal nerves (+83%, p= 0.001; and +108%,
p= 0.018, respectively) are significantly higher in men
than in women, while expression in men is lower in the
rectus abdominis muscle and the left frontal lobe
(42%, p= 0.015; 63%, p= 0.02, respectively)
(Table 4) compared to women. Finally, BSCL2-201
expression in the pituitary and the right cerebellum are
significantly lower in men than in women (40%,
p= 0.003, and 67%, p=0.015, respectively) (Table 4).
Influence of age on BSCL2 expression
A comparison of BSCL2 expression between young and
aged individuals (median age 61 years, Table 5) shows
that BSCL2 transcripts are generally expressed more
highly in younger subjects in both encephalic and non-
encephalic tissues. This observation is strongest for
BSCL2-203 (Table 5), weaker for BSCL2-201, and
weakest for BSCL2-205/207/210. An analysis of the
correlations between BSCL2-203 transcript and age
Fig. 4. Correlations between BSCL2 and age. Spearman’s correlation was calculated between BSCL2-203 relative expression normalized to the
18S gene and age. Significant correlations were observed for each zone: left temporal lobe, left amygdala and left hypothalamus, n= 13.
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significant negative correlations in the left temporal lobe
(r= 0.83, p< 0.001), left hypothalamus (r= 0.67,
p< 0.05), and left amygdala (r= 0.62, p< 0.05)
(Fig. 4).Putative role for seipin on oxidative stress protection
and peroxisome biogenesis in the CNSqPCR studies in human brains. Based on the previous
correlation results, the well-known role for oxidative stress
in aging (López-Otı́n et al., 2013), and our own preadipo-
cyte proteomic results from Celia’s Encephalopathy case
(Ruiz-Riquelme et al 2015) indicating that mitochondrial
superoxide dismutase (SOD2) and glutathione peroxi-
dase were distinctively modulated, we decided to quantify
the expression of key genes related to oxidative stress
protection by qPCR in the left temporal lobe, left
amygdala and left hypothalamus: PPARG, cytoplasmic
superoxide dismutase (SOD1), mitochondrial superoxide
dismutase (SOD2), catalase (CAT), peroxisomal biogene-
sis factor 1 (PEX1), peroxisomal biogenesis factor 11
gamma (PEX11G) and peroxisomal biogenesis factor 16
(PEX16). Spearman´s correlation coefficients were calcu-
lated and strong positive correlations were found between
BSCL2-203 and SOD1 and SOD2: BSCL2-203/SOD1,
r= 0.85, p< 0.001 and BSCL2-203/SOD2, r= 0.88,
p< 0.001, in left amygdala; BSCL2-203/SOD1,
r= 0.79, p< 0.05 and BSCL2-203/SOD2, r= 0.82,
p< 0.05, in left temporal lobe; BSCL2-203/SOD1,
r= 0.95, p< 0.001 and BSCL2-203/SOD2, r= 0.82,
p< 0.05, in the left hypothalamus. We found an impor-
tant positive correlation between PPARG and BSCL2-
203 in the amygdala and hypothalamus (r= 0.93,
p< 0.001, in left amygdala; r= 0.9, p< 0.001, in left
hypothalamus). Considering that PPARG plays an impor-
tant role in the activation of peroxisome proliferation, we
measured the expression of PEX1, PEX11G, and
PEX16. PEX1 encodes peroxisome biogenesis factor 1,
an ATP-ase anchored to the peroxisomal membrane,
and plays a role in protein import into peroxisomes and
peroxisome biogenesis. PEX11G, member of the
PEX11 family proteins, is involved in peroxisome fission,
while PEX16, a PPARG target gene, is required for de
novo synthesis of peroxisomes. BSCL2 did not correlate
with PEX1 when applying partial correlation coefficients,but positive correlations were found between BSCL2-
203 and PEX11G: r= 0.67, p< 0.05 in left hypothala-
mus, r= 0.65, p< 0.05 in left temporal lobe, and
r= 0.62, p< 0.05 in left amygdala; and also between
BSCL2-203 and PEX16 in left amygdala: r= 0.81,
p< 0.05. The catalase enzyme (CAT), present in perox-
isomes, correlated with BSCL2-203 in left hypothalamus:
r= 0.82, p< 0.05, in left temporal lobe: r= 0.91,
p< 0.05, and in left amygdala, r= 0.63, p< 0.05
(Fig. 5).
In vitro studies. Since the observed correlations do not
imply causality, we differentiate SH-SY5Y cells stably
transfected with BSCL2 into a neuronal model cell line
in order to measure the expression of genes
significantly correlated with BSCL2 in human brains.
Morphological changes were observed after 3–5 days
(Fig. 6), and many SH-SY5Y cells stopped proliferating
and expanded an extensive network of long neurites. At
the end of differentiation (day 7), cells were evenly
distributed and developed a more rounded shape,
forming clumps of cell bodies linked by long processes
similar to axons (Fig. 6C).
Neuronal differentiation was assessed by quantifying
the mRNA expression levels of neurogenesis-related
genes specific for neural progenitors (NESTIN) and
mature neurons (NeuN/RBFOX3), playing an essential
role in the differentiation and maturation of neural
progenitor cells (Kim et al., 2009; Kim et al., 2013). The
results showed that the mRNA expression of both neu-
ronal markers was detected in non-differentiated cells
and significantly increased after 7 days of differentiation,
pointing toward a more neuronal phenotype. NESTIN
and NeuN/RBFOX3 increased approximately 4- to 5-fold
and 2- to 10-fold, respectively, (Fig. 7A, B). The expres-
sion of the BSCL2-203 transcript was much higher in
BSCL2-cells than in control cells (+3024%) (Fig. 8A).
While there was no significant difference for PEX1,
significantly higher relative expression was seen for
PEX11G (+491%) (Fig. 8H), PEX16 (+181%)
(Fig. 8G), PPARG (+93%) (Fig. 8C), the antioxidant
enzymes SOD1 (+33%) (Fig. 8D), SOD2 (+25%)
(Fig. 8E), and CAT (+58%) (Fig. 8F).
Confocal microscopy studies in human brains. Confo-
cal microscopy was used to localize seipin and PEX16
expression in the hypothalami of healthy human brains
Fig. 5. Correlations between BSCL2 and other genes. Spearman’s correlations were calculated for BSCL2-203, CAT, PEX11G, PEX16, PPARG,
SOD1 and SOD2 relative expressions, normalized to the RPII gene. Significant correlations were observed in the following zones: left temporal lobe,
left amygdala and left hypothalamus, n= 13.
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Fig. 6. Morphological comparison between undifferentiated and
differentiated SH-SY5Y, Morphological comparison between (A)
undifferentiated and (B) differentiated SH-SY5Y cells over 7 days.
Phase contrast light microscopy and GFP fluorescence images
visualized under 10 magnification. Small red box indicates zoomed
area (C), shown under 20 magnification.
Fig. 7. Variation of neuronal markers after differentiation. Relative
expression of neuronal markers: (A) NESTIN and (B) NeuN/
RBFOX3, *p< 0.05 vs basal. All samples were analyzed in duplicate,
n= 4. Results were normalized to the RNA polymerase II gene.
S. Sánchez-Iglesias et al. / Neuroscience 396 (2019) 119–137 131and the PELD case. Image analysis revealed that seipin
and PEX16 are expressed in neurons in the
hypothalamic nuclei of both controls but not the PELD
index case (Fig. 9A–C). Interestingly, we only found
cytoplasmic seipin in neurons (and not in astrocytes or
oligodendrocytes). The main pattern observed in control
brain regions was what we classified as the ‘‘granular
profile,” in which seipin is scattered throughout the
neuronal cytoplasm and PEX16 appears to be closely
intertwined in the free spaces (Fig. 9A, B) very close to
seipin, with a shape resembling vesicles (Fig. 9D). We
also observed intranuclear PEX16 and seipin in control
hypothalamus images (Fig. 9B). Finally, the seipin
observed in neurons was localized in the cytoplasm in
samples from Celia’s Encephalopathy case, and the
staining was clearly diffused within the neuronal body
and the proximal segment of the axons. There were
more seipin-containing nuclei in Celia’s Encephalopathy
case compared to the control, while no PEX16 was
found in the hypothalamus of this patient (Fig. 9C).
DISCUSSION
This study describes the differential expression of the
BSCL2 in the human brain and other tissues, and
identifies BSCL2-203 as the major transcript in the
CNS. Remarkably, expression of this transcript appears
to be reduced in the more primitive regions of the brain
(diencephalon, mesencephalon and rhombencephalon).
BSCL2-205/207/210 is primarily expressed in theextraneural tissues, and the transcript responsible for
the Celia-seipin (BSCL2-201) is expressed very little but
mainly in the caudate, one of the nuclei affected earliest
in Celia’s Encephalopathy (Araujo-Vilar et al., 2018).
These results indicate specific tissue functions for the dif-
ferent BSCL2 transcripts, and these results coupled with
the observation that the 64 amino acids corresponding
to exon 1 and part of exon 2 of the BSCL2-203 transcript
are identical or quasi-identical in hominidae primates
(100–98%), very similar in other catarrhine primates
(95%), and similar in platyrrhine primates (86–89%), while
similarities are reduced in prosimians (75–55%) and in
mice (52%) (Fig. 10) suggest that the longer transcript
should play some role in the encephalization process.
To the best of our knowledge, this is the first time that
BSCL2 transcript expression is mapped in the different
regions of human brain. In mice, Garfield et al. (2012)
using in situ hybridization to map the location of Bscl2
mRNA-positive cells, found that the regions with strong
expression were the basal forebrain, hippocampus,
hypothalamus, dorsal and ventral brainstems, with low
expression in the cortex, moderate expression in the mid-
brain and no detectable expression in the caudate puta-
men. On the other hand, Liu et al. (2016) found a
similar expression pattern of seipin in the CNS using
immuno-histochemical staining, however with some dis-
crepancies like in the caudate putamen. While in our
study, we found highest BSCL2 expression in caudate,
putamen, cerebellum and protuberance, and mostly in
Fig. 8. Relative gene expression in SH-SY5Y differentiated cells overexpressing BSCL2-203 transcript. Relative expression of: (A) BSCL2-203, (B)
PEX1, (C) PPARG, (D) SOD1, (E) SOD2, (F) CAT, (G) PEX11G, (H) PEX16, *p< 0.05 vs cells transfected with empty vector. All samples were
analyzed in duplicate, n= 4. Results were normalized to the RNA polymerase II gene.
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Fig. 9. Confocal microscopy images. Confocal microscopy images (under 63 magnification with
2-zoomed images also included) showing immunofluorescence staining in the hypothalamus (HT) of
(A) one male control case (59-year-old), (B) one female control case (75-year-old), and (C) the PELD
index case, for PEX16 (green, Alexa 488), seipin (red, Alexa 555), and DAPI to label nuclei. Maximum
image projection shows the granular profile (green arrow), intranuclear seipin (white arrow), and
intranuclear PEX16 (yellow arrow), and merged images show no overlap between PEX16 and seipin
(B). Analysis of the view from one section from the male control case indicates that PEX16 labeling
was located as a peripheral ring, suggesting membrane labeling of vesicle-like PEX16 (D). Scale bar
25 and 50 mm. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
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could explain these discrepancies.
We have also found that the expression of seipin is
noticeably reduced in the temporal lobe, amygdala andhypothalamus of the left
hemisphere with age, all areas
associated with memory and its
consolidation, and the limbic
system. Given that mitochondrial
dysfunction is one of the
hallmarks of aging (López-Otı́n
et al., 2013), and that the pro-
teomic results in preadipocytes of
Celia’s Encephalopathy index case
(Ruiz-Riquelme et al., 2015b) indi-
cated that mitochondrial superox-
ide dismutase (SOD2) and
glutathione peroxidase were dis-
tinctively modulated, it is not sur-
prising to find strong positive
correlations between BSCL2 and
protective enzymes against oxida-
tive stress such as CAT, SOD1
and SOD2. The positive correla-
tions between BSCL2 and PPARG,
in agreement with other studies (Li
et al., 2015; Qian et al., 2016; Zhou
et al., 2016), CAT, SOD1, or SOD2
could be explained by the impor-
tant role played by PPARG in the
activation of peroxisome prolifera-
tion, ultimately protecting against
neurodegeneration by reducing
the production of reactive oxygen
species (Nordgren and Fransen,
2014; Cipolla and Lodhi 2017). On
the other hand, peroxisomal prolif-
eration also reduces beta-amyloid-
induced toxicity in hippocampal
neurons, reducing neuronal death
and the loss of the neuritic network
(Santos et al., 2005).
We investigated whether seipin
is truly related to protective
enzymes and peroxisomes in
order to confirm our qPCR results
in human brains. The significantly
increased expression of the
PEX11G, PEX16, SOD1, SOD2,
CAT, and PPARG genes
corroborated the relationship
between seipin and the protective
proteins to oxidative stress in
differentiated SH-SY5Y cells
overexpressing BSCL2. Confocal
microscopy in the hypothalami of
healthy human brains also
confirmed the close juxtaposition
of seipin and PEX16, the latter
appearing with a vesicle-like
shape. This key protein for
peroxisomal biogenesis isrequired for the de novo synthesis of peroxisomes (Kim
et al., 2006) and is known to target to the ER before being
trafficked to peroxisomes (Hua et al., 2015). Hofer et al.
Fig. 10. Seipin topology and homology. (A) The 462-residue-long form of seipin has two transmembrane helices, the N- and C-cytosolic-termini
appear to be variable among species, but the central domain loop at the lumen of the ER is highly conserved (B). CYT: cytoplasmic, TMD:
transmembrane, LUM: lumenal.
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whose expression regulates peroxisome number and lipid
metabolism, and demonstrated that it is also required for
adipogenesis (Hofer et al., 2017). Studies in rodents have
shown the beneficial effects of the pharmacological acti-
vation of peroxisome proliferator-activated receptors in
Parkinson’s disease and dyskinesia models (Barbiero
et al., 2014; Grover et al., 2013).
The profiles observed in the confocal images suggest
that seipin is involved in peroxisome biogenesis, probably
at an early phase. The juxtaposition of seipin and PEX16
observed in some neurons is consistent with the potential
close proximity of peroxisomes and lipid droplet
biogenesis areas (Binns et al., 2006), suggesting that per-
oxisomes and seipin are intimately associated. We can
further speculate that peroxisomes with vesicle-like
shapes may be pre-peroxisomal vesicles emerging from
the ER. It should be noted that the structure of the lipid
droplets and the peroxisomes are similar, both emerge
from the ER, and there is a dialog between both orga-
nelles (Shai et al., 2016). In this line, very recently and
during the course of the review of this manuscript,
Wang et al. 2018 identify in yeasts Pex30 as a factor
cooperating with seipin in the biogenesis of both lipid dro-
plets and pre-peroxisomal vesicles from the ER. In ouropinion, this recent Wang’s paper reinforces our hypothe-
sis about the role of seipin in peroxisomes biogenesis. On
the other hand, peroxisomes are very abundant in neu-
rons and play a key role in protection against oxidative
stress, and are also critical for the synthesis of phospho-
lipids. Finally, the peroxisome biomarker PEX16 is barely
detectable in the brain of the PELD case, where seipin is
also scarce. Taken together, these data may suggest that
seipin is playing a role in peroxisome biogenesis as a
regulator of peroxisomal protein sorting during the first
steps of biogenesis from the ER, similarly to what hap-
pens in the nascent lipid droplets (Shai et al., 2016;
Wang et al. 2018), or could act as an essential factor in
the recruitment of other peroxisomal membrane proteins
to the ER together with PEX16, which subsequently trans-
ports them to the peroxisomes (Kim and Mullen, 2013).
Correlation studies of gene expression, lentiviral overex-
pression experiments, as well as immunohistochemical
and localization studies have allowed us to consolidate
our hypotheses regarding the pathogenetic mechanisms
of Celia’s Encephalopathy (Ruiz-Riquelme et al., 2015).
Seipin appears to have specific functions in the CNS,
and could act as a neuroprotector, modulating the expres-
sion of SOD and CAT via PPARG by unknown mecha-
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against neurodegeneration. The fact that seipin may be
playing a role in peroxisome biogenesis makes them an
interesting potential therapeutic target.
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Garcı́a Á, et al. (2015) Larger aggregates of mutant seipin in
Celia’s encephalopathy, a new protein misfolding
neurodegenerative disease. Neurobiol Dis 83:44–53. https://doi.
org/10.1016/j.nbd.2015.08.006.
Salo VT, Belevich I, Li S, Karhinen L, Vihinen H, Vigouroux C, Magré
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